Novocure

Novocure is a pioneering oncology company founded in 2000 by Professor Yoram Palti, with the mission to revolutionize the way cancer is treated through its innovative Tumor Treating Fields (TTFields) therapy. Based on over 20 years of research, TTFields is a form of electric field therapy designed to disrupt the cancer cell division process, providing a non-invasive treatment option that can be used in conjunction with other therapies. Novocure aims to extend survival in patients with aggressive forms of cancer, including glioblastoma and mesothelioma, through its unique approach that spares healthy tissues while targeting malignant cells.

The company was born out of Professor Palti's exploration of electric fields in a basement laboratory in Haifa, Israel. What started as a theoretical exploration has now transformed into a global enterprise with over 1,400 employees dedicated to improving cancer treatment outcomes. Novocure operates across various regions, including North America and Europe, and is listed on the NASDAQ. The company's commitment to innovation has resulted in significant clinical trial successes, regulatory approvals, and a growing patient community that relies on their advanced therapy. With its focus on patient-centered outcomes, Novocure continues to strive towards making impactful differences in the lives of those battling cancer.